Results 181 to 190 of about 109,553 (260)
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Epstein-Barr Virus (EBV)-Positive Diffuse Large B-cell Lymphoma Masquerading As Lupus Pneumonitis in a Young Woman With Systemic Lupus Erythematosus: A Diagnostic Odyssey. [PDF]
Anya OO, Mosallaei S, Wysham N.
europepmc +1 more source
A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma. [PDF]
Mozessohn L +17 more
europepmc +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Predictive model for survival outcomes in rare primary glandular diffuse large B-cell lymphoma. [PDF]
Lu J, Liang C, Zhu X.
europepmc +1 more source
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó +14 more
wiley +1 more source
Atypical Ulcerated Cutaneous Presentation of Diffuse Large B-Cell Lymphoma: A Case Report. [PDF]
Nogueira P +4 more
europepmc +1 more source
Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma
British Journal of Haematology, EarlyView.
Zachary Hunzeker +10 more
wiley +1 more source

